IGNITE
21 Dec 2020
Trial Summary
IGNITE a phase II signal seeking trial of adavosertib (AZD1775) targeting recurrent high grade serous ovarian cancer (HGSC) with cyclin E1 (CCNE 1) over expression with and without gene amplification.
Acronym:
IGNITE
ACTRN/NCT /ethics:
ACTRN12619001185156
Scientific title:
Adavosertib targeting Cyclin E1 altered high grade serous ovarian cancer (HGSC) | IGNITE
Sponsor / Cooperative group:
ANZGOG
Trial & Patient Characteristics
| Cancer Type | Gynaecological |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | Female |
| Tumour Stream | - |
| Cancer Stage | All stages |
| Anticipated Start Date | 2020-03-01 |
| Anticipated End Date | 2023-03-01 |
Participating Hospitals
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Alex Scott-Hoy |
| alex.scott-hoy@sa.gov.au | |
| Phone | 08 8204 4830 |
| Principal Investigator | Dr Ganessan Kichenadasse |
| Recruitment Status | Not Yet Recruiting |